Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Invion Ltd

IVX.AX ✓ COMPLIANTFree checks used up today ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.03

▼ -5.00%

Market Cap $2.90M · Vol 2.88K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$2.90M

Micro Cap

Div Yield

N/A

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

45.45

Momentum

Beta

0.13

vs Market

52W High

$0.08

64.00% below

52W Low

$0.02

19.80% above

Volume

2.88K

Avg 53.92K

P/B

0.72

Price-to-book

ROE

N/A

Return on equity

Free Float

53.34%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Invion Ltd (IVX.AX) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IVX.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

-11.63%

+2.70%

-44.12%

YTD

-59.14%

-62.00%

-91.75%

-97.29%

Financials & Valuation

TTM · Annual

Total Revenue	$266.18K
Net Income	$-3,897,447.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-1,472.06%
Net Profit Margin	-1,464.23%
ROE	N/A
ROA · ROIC	-63.81% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	8.19
P/B	0.72
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	109.20M

Technical Indicators

50-Day SMA	$0.03
200-Day SMA	$0.04
RSI (14)	45.45
Beta	0.13
52-Week High	$0.08
52-Week Low	$0.02

Volume Today	2.88K
Avg Daily Volume (30D)	53.92K
Relative Volume	0.05x
Volatility (10D)	64.13
Volatility (30D)	76.05
Free Float	53.34%

Analyst Consensus

N/A

Current Price $0.03

Mean Target N/A

52W Low$0.02 52W High$0.08

Current

Target

$0.02 $0.08

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG001T62XV3

ISINAU000000IVX4

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG +1.56% ONC BeOne Medicines AG +1.24% 068270.KS Celltrion, Inc. -2.13% MEDP Medpace Holdings, Inc. +1.55% ABVX Abivax SA -1.01%

Company Profile

Invion Limited is an Australia-based life science company. The Company is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The Company is developing Photosoft technology as a Photodynamic Therapy (PDT). PDT uses non-toxic photosensitizers and light to selectively kill cancer cells and promote an anti-cancer immune response. PDT also offers an alternative treatment option aimed at achieving complete tumor regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. It holds the Australia and New Zealand license rights and distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. The Company’s wholly owned subsidiary is Epitech Dermal Science Pty Ltd.